Alternate-Day Buprenorphine Administration. Phase VI - 7

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000225

NIDA-06969-7

R01-06969-7

Details and patient eligibility

About

The purpose of this study is to determine if four times a subject's daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects.

Sex: All

Ages: 21 to 51 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.